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Chapter I. General overview 
 
1.1. Background and purposes 
  The prevalence of type 2 diabetes mellitus (T2DM), leading to diabetic 
complications, has been increasing worldwide. The possible applications of 
diabetic patient-derived stem cells in stem cell therapy are limited because 
their characteristics are still not fully understood. This study aimed to elucidate 
the characteristics of human type 2 diabetic adipose tissue-derived 
mesenchymal stem cells (dAT-MSCs) under normoxic and hypoxic conditions 
in vitro and in flap mouse model of wound healing. Furthermore, I aimed to 
investigate the characteristics of microvesicles isolated from human non-
diabetic adipose tissue-derived mesenchymal stem cells (nAT-MSCs) and 
their effects on dAT-MSCs. 
 
1.2. Materials and methods 
I characterized nAT-MSCs and dAT-MSCs by fluorescence-activated 
cell sorting (FACS) and differentiation assay. Gene and protein expression 
levels were performed by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR), Western blot, and ELISA assay. Inhibition of 
early growth response-1 (EGR-1) was carried out by small hairpin RNA 
targeted EGR-1 (shEGR-1) and treatment with PD98059 inhibitor. Chromatin 
immunoprecipitation (ChIP) assay was performed to find the binding of 
hypoxia-inducible factor-1α (HIF-1α) on EGR-1 promoter. The scratch assay 
and flap mouse model were used as in vitro and in vivo wound healing 
assays.   
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1.3. Results 
dAT-MSCs have potential to differentiate into other cell linages and 
express MSC surface markers. EGR-1 and its target genes were highly 
expressed in dAT-MSCs in comparison to nAT-MSCs, resulting in increasing 
of genes and protein associated with cell adhesion, insulin resistance, and 
impaired wound healing in flap mouse model. Interestingly, under hypoxic 
conditions, HIF-1α can bind to the EGR-1 promoter in dAT-MSCs, but not in 
nAT-MSCs. The effects of EGR-1 were diminished by a shEGR-1 and a 
treatment with extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor 
(PD98059), suggesting that the expression of EGR-1 was upregulated in 
dAT-MSCs by ERK1/2 signaling pathway and HIF-1α regulation under 
normoxic and hypoxic conditions. Mice injected dAT-MSCs with shEGR-1 
were improved their wound healing capacity.  
Furthermore, I found that human nAT-MSC-derived microvesicles 
(nMVs) could improve dAT-MSC function by altering miRNA and mRNA 
expressions, which enhanced their migration ability in vitro and wound 
healing capacity in flap mouse model.  
 
1. 4. Conclusion 
dAT-MSCs increased in cell adhesion in vitro and impaired wound 
healing in vivo. Knockdown of EGR-1 in dAT-MSCs and the modification of 
nMV-treated dAT-MSCs enhance their wound healing capacity. This study 
suggests new therapeutic targets for improving dAT-MSC function before 
applying for clinical treatment. 
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1.5. Abbreviations 
 
T2DM  type 2 diabetes mellitus 
AT-MSCs adipose tissue-derived mesenchymal stem cells 
nAT-MSCs AT-MSCs from non-diabetic donors  
dAT-MSCs AT-MSCs from diabetic donors 
RT-PCR  reverse transcription polymerase chain reaction  
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Runx2  Runt-related transcription factor 2  
ALP   alkaline phosphatase 
PPARγ2 peroxisome proliferator-activated receptor gamma-2 
EGR-1 early growth response-1 
Cyr61  Cysteine-rich angiogenic inducer 61 
Col4  type IV collagen  
Inαv   Integrin αv  
IL6  Interleukin 6 
bFGF  basic fibroblast growth factor  
TGF-β transforming growth factor beta 
ERK1/2 extracellular signal-regulated kinase 1/2  
AKT  a serine/threonine-specific protein kinase 
SDF-1  stromal cell-derived factor 1  
CXCR4 C-X-C chemokine receptor type 4  
CXCR7 C-X-C chemokine receptor type 7 
CCL2  chemokine (C-C motif) ligand 2  
ANGPTL4  angiopoietin-like 4   
nMVs  microvesicles (MVs) derived from nAT-MSCs 
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Chapter II.  Increased expression of EGR-1 in diabetic human 
adipose tissue-derived mesenchymal stem cells reduces their 
wound healing capacity 
 
2.1. Introduction 
2.1.1. Type 2 diabetes mellitus and chronic wound  
Type 2 diabetes mellitus (T2DM) has increased dramatically from 176 
to 410 million people within 23 years (1990 – 2013) and become a problem 
worldwide [1]. T2DM is a long-term metabolic disorder that is described by 
high blood sugar and insulin resistance [2,3]. For temporary symptomatic 
treatments of T2DM, the patients undergo an intensive diet and exercise 
program as well as intervening with insulin or medications including 
metformin, acarbose or thiazolidinediones [4–6]. However, the onset of type 
T2DM leads to the development of the long-term consequences of 
microvascular and macrovascular complications [7,8].  
Chronic wound, a common diabetic complication, is four times greater 
in diabetic patients than in non-diabetic people [9,10]. Chronic wound is a 
non-healing wound representing a major healthcare burden caused by 
delaying in wound healing process, which can be divided into four overlapping 
phases: coagulation and hemostasis, inflammation, proliferation, and 
remodeling [11,12]. 
 
2.1.2. Hypoxia regulates key factors involved in pathogenesis  
Oxygen concentration in tissues is a key factor for cell and organ 
survival [13]. Under physiological conditions (physioxia), partial oxygen 
pressure (pO2) results in the balance between oxygen delivery and its 
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consumption. The alteration of tissue environment leading to a decrease in 
pO2 from physioxia is called hypoxia [13,14]. Hypoxic conditions have been 
observed in many different pathological situations like tumor development, 
diabetes, coronary heart disease, and transcient ischemia [13–15]. 
In T2DM patients, hyperglycemia and insulin resistance both seem to 
have important roles in the pathogenesis of diabetic complications such as 
chronic wound, which decrease production of trophic factors for cells and 
tissues as well as abnormalities in blood flow, which results in hypoxia or 
ischemia causing tissue disease and degeneration [7,15,16].  
Hypoxia stabilizes an important transcription factor, hypoxia inducible 
factor (HIF)-1α. HIF-1α accumulates in the nucleus and binds to short DNA 
sequences near or in the promoters of target genes called hypoxia-response 
elements (HREs) to regulate the expression of HIF-1α target genes under 
hypoxic conditions [17–19]. Hypoxia-activated cell death leads to impaired 
endothelial cell barrier function and an increase in vascular permeability, 
leakage, and necrosis [14,15].  
Hypoxia also increases the transcriptional activation of early growth 
response-1 (EGR-1) in mononuclear phagocytes and hepatoma-derived 
cells  [20,21]. EGR-1 was first identified by Sukhatme and colleagues 
(1988), preferentially binds to GC-rich DNA sequences [22]. EGR-1 is rapidly 
and transiently expressed in the nucleus of many different cell types 
including endothelial cells (ECs), fibroblasts, vascular smooth muscle cells 
(VSMCs), monocytes, and macrophages [23–25].  
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2.1.3. The expression of early growth response-1 gene associated with 
type 2 diabetes mellitus 
EGR-1 is highly expresses in the abdominal fat tissue of diabetic 
patients and epi fat tissue of db/db mice [26]. Insulin increased EGR-1 
expression through activation of the extracellular signal-regulated kinase 
(ERK) 1/2 signaling pathway [26,27]. The increase in phosphorylation of 
ERK1/2 signaling elevates the expression of EGR-1, PTEN, and GGPPS 
leading to insulin resistance in mouse adipocytes [26,27]. 
EGR-1 activates the expression of many growth factors such as 
bFGF and TGF-β, adhesion molecules (Cyr61, ICAM-1 and MCP-1), and the 
inflammatory signaling cascade of TNF-α and IL-6. Thus, high EGR-1 
activity is involved in the pathogenesis of atherosclerosis, restenosis, and 
cardiovascular diseases [23–25]. A previous study demonstrated that 
atherosclerosis and vascular inflammation were decreased in homozygous 
Egr-1-/-/apoE-/- double-knockout mice [25].  
2.1.4. Potencies of adipose tissue-derived mesenchymal stem cells in 
clinical applications 
Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are 
considered as an important potential source due to many advantages: easy 
isolation, abundant amount, and auto-transplantation [28–30]. Like hMSCs 
form other sources, AT-MSCs express hMSC surface markers and possess 
self-renewal capacity, long-term viability, and multilineage potential [29,30].  
Earlier studies in cell-based therapies for diabetic wound healing focused 
mainly on fibroblasts; however, recent studies have elucidated the benefits of 
mesenchymal stem cells (MSCs) [31,32]. The therapeutic effect of AT-MSCs 
is dependent on their capacity to secrete soluble factors, including growth 
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factors, cytokines and chemokines that inhibit cell apoptosis, stimulate cell 
proliferation, promote vascularization and modulate the immune response 
[32–34]. It has been reported that AT-MSCs are able to stimulate proliferation, 
migration and matrix production of cultured dermal fibroblasts and endothelial 
cells via a paracrine patterns [28,34,35]. The activity of AT-MSCs in the in 
vivo wound healing appears to stimulate early inflammation response and 
promotes functional regeneration of the tissues by mesenchymal cells, 
fibroblasts, epithelial cells, and keratinocytes during the inflammation and 
proliferation phase [32,34,35].  
Other report from my laboratory, Kimura et al. (2014) demonstrated 
that mice transplanted with AT-MSCs increased the degree of calcification at 
the joint region of bone fracture more than mice transplanted with bone 
marrow-derived MSCs (BM-MSCs) or dental tissue-derived MSCs (DT-
MSCs). In addition, AT-MSCs showed higher ability to promote the blood flow 
and recruit CD45- and F4/80-positive cells in ischemic region of vascular 
occlusion mouse model than those of BM-MSCs and DT-MSCs [36], 
suggesting the high capacity of AT-MSCs in wound healing compared to BM-
MSCs and DT-MSCs. 
 In spite of that, it has been demonstrated that dAT-MSCs have different 
gene expression profiles from nAT-MSCs and exhibited a low capacity for 
differentiating into osteoblasts and chondrocytes in comparison to nAT-MSCs 
under in vitro conditions that mimicked hyperglycemia [37]. The present study 
aimed to elucidate the characteristics of dAT-MSCs under normoxic and 
hypoxic conditions in vitro and in vivo, in a mouse model of wound healing, to 
allow for a better understanding of the potential future applications of dAT-
MSCs in stem cell therapy.  
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2.2. Materials and methods 
 
2.2.1. Antibodies 
The following antibodies were used for the analyses of stem cell 
markers: Fluorescein isothiocyanate (FITC)-labeled anti-HLA-ABC (311404, 
BioLegend, San Diego, CA), FITC-labeled anti-CD90 (328107, BioLegend), 
phycoerythrin (PE)-labeled anti-CD13 (301701, BioLegend), PE-labeled anti-
CD166 (559263, BD Pharmingen), PE-labeled anti-CD105 (323206, 
BioLegend), PE-labeled anti-CD73 (550257, BD Pharmingen), PE-labeled 
anti-HLA-DR (307606, BioLegend), PE–labeled anti-CD31 (303106, 
BioLegend), PE-labeled anti-CD14 (301806, BioLegend), allophycocyanine 
(APC)–labeled anti-CD45 (555485, BD Biosciences, San Jose, CA), and 
FITC-labeled anti-CD34 (555821, BD Biosciences). APC-labeled anti-IgG1 
(555751, BD Biosciences), PE-labeled anti-IgG1 (555749, BD Biosciences), 
FITC-labeled anti-IgG1 (555748, BD Biosciences) were used as the isotype 
controls. After staining the nAT-MSCs and dAT-MSCs with fluorochrome-
conjugated antibodies, the cells were sorted and analyzed using a MoFlo 
(MoFlo XDP; Beckman Coulter, Brea, CA).  
The following primary antibodies were used for the Western blotting 
analyses: rabbit mAb Akt (11E7, #4685) and Phospho-Akt (Ser473) (D9E, 
#4060S); p44/42 ERK1/2 (137F5, #4695) and Phospho-p44/42 ERK1/2 
(D13.14.4E, #4370S); rabbit anti-IRS-1 (D23G12) and rabbit antibody 
phospho-IRS-1 (serine 636/639) (2388) (Cell Signaling Technology, Danvers, 
Massachusetts); rabbit anti-EGR-1 (588, sc-110); goat anti-β Actin (C-11, sc-
1615); goat anti-Lamin B (M20, sc-6217) (Santa Cruz Biotechnology, Santa 
Cruz, CA); rabbit anti-HIF-1α (NB100-479, Novus Biologicals, Littleton, CO); 
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HRP-conjugated goat anti-rabbit IgG (656120) and rabbit anti-goat IgG 
(611620) (Invitrogen, Carlsbad, CA) were used as the secondary antibodies.  
 
2.2.2. The isolation of AT-MSCs 
 The studies are performed according to the amended Declaration of 
Helsinki and all of the experiments were approved by the ethics committee 
of the University of Tsukuba. Human adipose tissue was obtained after 
obtaining informed consent from diabetic (n=3, HbA1c>7.0, long-term 
treatment) and non-diabetic (n=3) donors, male, age=59±10 years, who 
were undergoing procedures in the Department of Cardiovascular Surgery, 
University of Tsukuba Hospital, Tsukuba, Japan (Table 3). The isolation of 
AT-MSCs was performed as previously described [36].  
Cells were cultured in Iscove's Modified Dulbecco's Medium (12200-
069, Invitrogen), 10% FBS, 2 mg/mL L-glutamine (25030, Invitrogen), 5 
ng/mL recombinant human bFGF (Peprotech, 064-04541, London, United 
Kingdom) at 37°C in 5% CO2 and a humidified atmosphere. After 3 days, the 
medium containing non-adherent cells was removed and replaced with fresh 
medium. Frozen cell stocks were prepared using Cell Banker solution 
(ZENOAQ, Koriyama, Japan) and stored in liquid nitrogen for further 
experiments. All AT-MSCs used for the experiments of this study at passage 
5−8. 
 
2.2.3. The in vitro differentiation of AT-MSCs 
In vitro differentiation was performed as described previously [36]. 
Osteogenic and adipogenic differentiation were assessed on day 21 by 1% 
Alizarin Red S (Kodak, Tokyo, Japan) and Oil Red O (Muto Pure Chemicals, 
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Tokyo, Japan) staining, respectively. The final step of assessing the 
differentiation was to measure absorbance at 482 nm and 490 nm for Alizarin 
Red and Oil Red O staining, respectively using a spectrophotometer Gene 
QuantTM100, 4280 V1.6.1 (GE Healthcare, Tokyo, Japan).  
To assess chondrogenic differentiation, cell pellets were sectioned and 
stained with hematoxylin and eosin (Muto Pure Chemicals) and Toluidine blue 
(Muto Pure Chemicals) to visualize the control cells and chondrocytes, 
respectively. The cells were visualized with an Olympus IX71 microscope 
(Olympus, Tokyo, Japan) under UPlan FI (×10 and ×20). All of the 
differentiation experiments were performed independently. The nAT-MSC and 
dAT-MSC experiments were performed in triplicate. 
 
2.2.4. The cell proliferation assay 
AT-MSCs were plated at a density of 4 x 104 cells per 35-mm dish, and 
cultured under normoxic (20% O2, 37 °C) or hypoxic (5% O2, 37 °C) conditions. 
The cell culture medium was replaced every 4 days. Every 24 h, the cells 
were washed twice with PBS and dispersed into a single cell solution using 
0.05% trypsin/EDTA. The number of cells was counted using trypan blue 
(Invitrogen) exclusion for 10 days. 
 
2.2.5. shRNA transfection 
The shRNAs were designed for human EGR-1 (NM_001964, 
TRCN0000273850, Sigma-Aldrich, Louis, MO, USA). shRNA transfection was 
performed using hexadimethrine bromide transfection reagent (Sigma-Aldrich) 
according to the manufacturer’s protocol.   
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2.2.6. Insulin stimulation  
Insulin stimulation was performed as described previously [27]. nAT-
MSCs and dAT-MSCs were cultured under normoxic (20% O2, 37 °C) or 
hypoxic (5% O2, 37 °C) conditions until cells reached 80% confluence. 
Insulin (1000 nM) was added for 1 h to allow for the detection of IRS-1 
phosphorylation. 
 
2.2.7. Analysis of ERK1/2 activity in AT-MSCs  
nAT-MSCs and dAT-MSCs were cultured in normoxic (20% O2, 37 °C) 
or hypoxic (5% O2, 37 °C) conditions, until the cells reached 80% 
confluence. PD98059 (P215, Sigma-Aldrich), an inhibitor of ERK1/2, was 
used, according to the manufacturer’s protocol, at a concentration 50 µM for 
60 min to detect mRNA expression.  
 
2.2.8. Quantitative RT-PCR  
To examine the expression of genes related to osteogenic and 
adipogenic differentiation, nAT-MSCs and dAT-MSCs were assessed at day 
7 after induction. nAT-MSCs and dAT-MSCs were cultured under normoxic 
(20% O2, 37 °C) or hypoxic (5% O2, 37 °C) conditions for 5 days and RNA 
was extracted using an RNeasy mini kit (Qiagen, Valencia, CA).  
Total RNA (1 µg) was reverse transcribed using an RT-PCR kit 
(TOYOBO, Japan). cDNA was analyzed using a GeneAmp 7500Fast Real-
Time PCR System (Life technologies) using CYBR green reagent 
(TOYOBO). The expression levels of the target genes were analyzed using 
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the ΔΔCt method. The sequences of the primer sets used for the PCR 
reactions are shown in Table 1. 
 
2.2.9. Western blot 
 nAT-MSCs and dAT-MSCs were cultured under normoxic (20% O2, 37 
°C) or hypoxic (5% O2, 37 °C) conditions for 4 days. Whole cell lysates were 
prepared with RIPA buffer (25 mM Tris, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholic acid, 0.1% SDS) for 30 min and centrifuged at 15,000 
rpm at 4 °C for 10 min. The collected supernatants were used for the 
Western blotting analyses. In each group, an equal amount of protein was 
electrophoresed on 8.5% sodium dodecyl sulphate–polyacrylamide (SDS-
PAGE) gel and then transferred onto PVDF membranes (Immobilon-P, 
Millipore). The membranes were then incubated with a primary antibody as 
indicated. HRP-conjugated goat anti-rabbit IgG or rabbit anti-goat IgG was 
used as secondary antibody, and an enhanced chemiluminescence HRP 
substrate (Millipore) was used for detection. Goat anti-β-Actin and goat anti-
Lamin B were used as the internal controls for monitoring protein loading 
and transfer. 
 
2.2.10. ELISA assay 
nAT-MSCs and dAT-MSCs were cultured under normoxic (20% O2, 37 
°C) or hypoxic (5% O2, 37 °C) conditions for 4 days. Then, cells were treated 
with PD98059 (50 µM) in fresh culture medium (IMDM) for 60 min. The 
quantitative concentration of IL-6 (interleukin-6) present in cell culture 
supernatants was measured by IL-6 high sensitivity human ELISA kit (D6050, 
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R&D systems, Minneapolis, USA) following the manufacturer’s protocol. 
 
2.2.11. Chromatin immunoprecipitation (ChIP) assay  
dAT-MSCs were cultured under normoxic (20% O2, 37 °C) or hypoxic 
(5% O2, 37 °C) conditions for 4 days. A ChIP assay was performed using a 
ChIP-IT Express Enzymatic Kit (Active Motif, Carlsbad, CA, USA) according 
to the manufacturer’s instructions. The extracted chromatin samples were 
enzymatically sheared and immunoprecipitated with rabbit anti-HIF-1α, and 
control IgG as the primary antibodies. The precipitated genome fragments 
were subjected to a PCR. The PCR primer set was designed for the HRE 
sequence on the EGR-1 promoter as follows:  
hEGR-1 -3k HRE sense (AGACTTCCACAGGCGATTCTGCTGC) and 
antisense –(GCAATTGGCATTCAACAAACAGTGG). 
 
2.2.12. Animal studies 
Female C57BL/6 mice were purchased from Charles River Japan, Inc. 
(Yokohama, Japan). All of the mice were maintained on a 12-h light/dark cycle 
in the Animal Research Center of the University of Tsukuba. All protocols of 
the protocols of the animal experiments were approved by the Animal Care 
Committee of the University of Tsukuba. The mouse skin flap model was 
performed as described previously [38]. Briefly, 10-week-old C57BL/6 mice 
were anesthetized and a peninsular shaped incision (3 cm × 2 cm) was made 
on the dorsal surface, generating an ischemia gradient by blood flow 
restriction. The mice were divided into 5 groups: PBS (n=5), nAT-MSC (n=30), 
dAT-MSC (n=30), dAT-MSC-mock (n=5), and dAT-MSC-shEGR-1 (n=6).  
In each of the AT-MSC transplantation groups, cells were injected 
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locally on the dorsal surface at 4 positions (5 x 105 cells/200 µL 
IMDM/mouse). Immunosuppression was induced by the intraperitoneal 
injection of cyclosporin-A (20 mg/kg body weight; Wako, Osaka, Japan) every 
2 days. The efficiency of wound healing of C57/BL6 mice with injection of 
cyclosporin-A was not different from that of BALB/c nu/nu mice without the 
cyclosporin-A treatment [69]. Therefore, C57/BL6 mice with the cyclosporin-A 
treatment were used in this study. After 7 days, 200 µL of Banderiraea 
simplicifolia-I (BS-I) lectin-TRITC (0.1 mg/mL; Sigma-Aldrich) was injected 
into the tail vein, approximately 30 min before sacrifice. Images of the 
ischemic flap were captured. The flap tissue was embedded and sectioned for 
analysis. 
 
2.2.13. Histological analysis 
The tissue structure and vessel formation were stained using 
hematoxylin and eosin counterstain and BS-I lectin-TRITC, respectively. The 
inflammatory cells in the ischemic tissue were examined by 
immunohistochemical staining with PE-labeled anti-CD45 (30F11, BD 
Pharmingen). Relative value of vessel per area was based on the 
fluorescence intensity ratio per each field and measured by Image J software 
(NIH, Maryland, USA). A number of CD45 cells were counted in each field. 
The presented data were the average of ten fields per data. 
 
2.2.14. Statistical analysis  
Student’s t-test was used to determine the significance of differences 
between two experimental groups. The one-way ANOVA, followed by 
Bonferroni post-hoc test (SPSS software, IBM Corp., NY, USA), was used to 
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determine statistical differences among three or four experimental groups. A 
P-value < 0.05 was considered to indicate statistical significance. All of the 
data are presented as the mean ± standard deviation (SD). 
 
2.3. Results 
 
2.3.1. The differentiation potential and the expression of mesenchymal 
stem cell surface markers in nAT-MSCs and dAT-MSCs 
AT-MSCs are known to possess the ability to differentiate into several 
types of mesenchymal cells and to express some mesenchymal stem cell 
markers [28–30]. In order to examine the differentiation potential of dAT-
MSCs, nAT-MSCs and dAT-MSCs were cultured under conditions that would 
induce differentiation into osteoblasts, adipocytes, and chondrocytes. Alizarin 
Red, Oil Red O, and Toluidine blue staining were performed to examine 
calcification in osteoblasts, lipid accumulation in adipocytes, and cartilage 
proteoglycan synthesis in chondrocytes, respectively (Fig. 1A).  
Both nAT-MSCs and dAT-MSCs had the same potential to differentiate 
into osteocytes and chondrocytes (Fig. 1A, 1B). On the other hand, the 
differentiation ability toward adipocyte lineage was higher in dAT-MSC than 
that in nAT-MSC. Consistent with these observations, the expression levels of 
the two adipocyte-specific genes (PPARγ2 [39] and adiponectin [40]) were 
greater in dAT-MSCs than in nAT-MSCs, whereas the expression levels of the 
osteogenic genes (Runx2 [41] and ALP [42]) in dAT-MSCs and nAT-MSCs 
were comparable (Fig. 1C).  
A flow cytometric analysis revealed that the MSC-specific cell surface 
markers except CD166/ALCAM were expressed at similar levels in both dAT-
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MSCs and nAT-MSCs (Fig. 2). CD166/ALCAM expressed higher in dAT-
MSCs compared to nAT-MSCs. It has been reported that CD166/ALCAM is a 
close structural and functional homolog of RAGE [43], and RAGE-mediated 
regulation of adiposity and inflammation associated with T2DM and diabetic 
vascular complications [44]. Collectively, these findings demonstrate that of 
these two types of AT-MSCs, dAT-MSCs possess a greater potential to 
differentiate into adipocytes; the other phenotypes were indistinguishable from 
nAT-MSCs. 
 
2.3.2. The ability to improve wound healing is impaired in dAT-MSCs in 
the mouse skin flap model 
The proliferation activity of nAT-MSCs and dAT-MSCs were 
examined under normoxic and hypoxic conditions. In the log phase, the 
average doubling time in nAT-MSCs and dAT-MSCs was similar under both 
normoxic and hypoxic conditions (Fig. 3A). As expected, both types of AT-
MSCs proliferated faster under hypoxic conditions. On day 7 of culture, 
when the cells reached confluence, the dAT-MSCs that were cultured under 
hypoxic conditions appeared to be difficult to dissociate into single cell 
suspensions by trypsinization. Even with an extended treatment time with a 
higher concentration of trypsin/EDTA, the number of countable dAT-MSCs 
was much lower due to cell aggregation (Fig. 3B).  
The increased cell aggregation and adhesion of the dAT-MSCs only 
appeared under hypoxic conditions. I hypothesized that the increased 
aggregation and adhesion of dAT-MSCs might affect their regenerative 
activity in ischemic tissue in vivo. To test this, the wound healing activity of 
AT-MSCs was examined using mice with an ischemic flap. Although the 
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injection of both AT-MSCs improved the recovery from injury at one week 
after surgery, the necrotic surface area was larger in the dAT-MSC injected 
mice than in the nAT-MSC injected mice (Fig. 4A, 4B).  
The H&E staining of the ischemic flap revealed a hypertrophic 
epidermis, which resembled normal wound healing, in the nAT-MSC-injected 
mice. In contrast, the hypertrophy of the epidermis was less evident in the 
dAT-MSC-injected mice (Fig. 4C). The improved wound healing of the nAT-
MSC-injected mice was also shown by Lectin-TRITC staining, which shows 
the active neovascularization. Notably, the formation of neovascularization 
was less prominent in the flap in the dAT-MSC-injected mice (Fig. 4C, 4D).  
At one week after surgery, the flap of the untreated mice showed 
significant CD45-positive cell infiltration, suggesting that the inflammation 
that occurred in response to tissue injury was prolonged (Fig. 4C, 4E). In 
contrast, the number of CD45-positive cells in the flap of the nAT-MSC-
injected mice was much lower than that in the untreated mice (Fig. 4C, 4E). 
A greater number of CD45-positive cells were observed in the flap of the 
dAT-MSC-injected mice than in the nAT-MSC-injected mice (Fig. 4C, 4E). 
Taken together, these findings indicate the impaired ability of dAT-MSCs to 
improve wound healing in the ischemic flap in mouse model of ischemia. 
 
2.3.3. The expression of EGR-1 is increased in dAT-MSCs  
To explore the molecular basis for the impaired wound healing effects 
of dAT-MSCs, I focused on EGR-1, a zinc finger transcription factor, since 
the overexpression of this molecule in adipocytes has been reported to 
promote insulin resistance in T2DM patients [26,27]. Indeed, EGR-1 protein 
was more abundant in dAT-MSCs than in nAT-MSCs under both normoxic 
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and hypoxic conditions (Fig. 5A). A quantitative RT-PCR revealed that the 
mRNA level of EGR-1 was significantly greater in dAT-MSCs than in nAT-
MSCs, indicating that EGR-1 was upregulated at the transcriptional level 
(Fig. 5B).  
Although the expression of EGR-1 is known to be rapidly and 
transiently induced by stress signals, including hypoxia, it is noteworthy that 
EGR-1 was highly expressed in dAT-MSCs, even under normoxic conditions. 
Consistent with these observations, the mRNA levels of the two target 
molecules of EGR-1 in adipocytes, PTEN and GGPPS [26,27], were higher 
in dAT-MSCs than in nAT-MSCs. Interestingly, although the level of EGR-1 
protein was comparable under normoxic and hypoxic conditions, hypoxia 
induced the expression of PTEN, but not GGPS1 (the gene encoding 
GGPPS) (Fig. 5C).  
A previous study reported that the phosphorylation of insulin receptor 
substrate-1 (IRS-1) at Ser636 was increased in skeletal muscle cells from 
T2DM patients due to an increase in basal MAPK activity [45]. Since EGR-1 
has been shown to augment Erk/MAPK signaling through the upregulation of 
PTEN and GGPPS [26,27], I examined whether the phosphorylation of 
Ser636/639 by IRS-1 was increased in dAT-MSCs by Western blot analysis 
(Fig. 5D). In the absence of insulin, I did not observe any phosphorylation of 
Ser636/639 of IRS-1 (data not shown).  In contrast, in the presence of insulin, 
the phosphorylation of Ser636/639 of IRS-1 was observed in dAT-MSCs 
under the normoxic conditions; this phosphorylation was further increased 
under hypoxic conditions (Fig. 5D) (in place of the phosphorylation of IRS-1 
on tyrosine sites [46,47]).  
Aside from its role in insulin signaling, EGR-1 has been shown to play 
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multiple roles in the regulation of the inflammatory response, fibrogenesis, 
and cell adhesion [48–52]. Since my findings showed that the wound healing 
effects in the mouse skin flap model were impaired in dAT-MSCs, the mRNA 
level of IL-6 in dAT-MSCs was more than 25-fold higher than that in nAT-
MSCs under both normoxic and hypoxic conditions, and the protein level was 
4-fold higher in dAT-MSCs compared to nAT-MSCs measured by ELISA 
assay (Fig. 6A).  
In addition, the mRNA levels of the cytokines and adhesion molecules 
that are known to be regulated by EGR-1 [49–52] using a quantitative RT-
PCR. I found that the expression levels of EGR-1 target cytokines (bFGF and 
TGF-β) were significantly higher in dAT-MSCs than in nAT-MSCs under 
hypoxic conditions (Fig. 6B). Although the mRNA level of bFGF was observed 
to be increased in dAT-MSCs in comparison to nAT-MSCs, irrespective of 
oxygen tension, the upregulation of TGF-β in dAT-MSCs was only observed 
under hypoxic conditions (Fig. 6B).  
Among the known EGR-1 target genes that encode cell adhesion 
molecules, Cyr61 and Col4 were more highly expressed in dAT-MSCs than in 
nAT-MSCs, irrespective of oxygen tension, whereas the increased expression 
of Inαv was only observed under hypoxic conditions (Fig. 6C). Collectively, 
these data suggest an important role of EGR-1 in regulation many target 
genes, which respond in insulin resistance, cell adhesion, and inflammation 
that may associate with the impaired wound healing activity of dAT-MSCs in 
vivo. 
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2.3.4. Activated ERK1/2 signaling is the major upstream signal of EGR-
1 activation in dAT-MSCs 
Although EGR-1 expression is known to be induced by hypoxia, the 
direct effect of HIF-1α on EGR-1 gene transcription is controversial, since 
hypoxia-induced EGR-1 expression is retained in hepatoma cells which lack 
HIF-1β (a heterodimeric partner of HIF-1α) [21]. In support of this hypothesis, 
the induction of HIF-1α was similarly observed in both types of AT-MSCs, 
despite EGR-1 expression being constitutively activated in dAT-MSCs (Fig. 
7A). Interestingly, a ChIP assay revealed that, under hypoxic conditions, HIF-
1α binds directly to a putative HRE within the EGR-1 promoter in dAT-MSCs, 
but not in nAT-MSCs (Fig. 7B).  
It has been shown that EGR-1 expression is induced by various stress 
signals, including tissue injury, oxidative stress and hypoxia [48,50,51]. EGR-
1 expression is induced through the activation of extracellular signal-regulated 
kinase 1/2 (ERK1/2) [53,54]. In order to determine the upstream signaling that 
is involved in the activation of EGR-1 in dAT-MSCs, I examined the effect of 
PD98059, an inhibitor of MAPK/ERK kinase, on the EGR-1 protein levels in 
AT-MSCs. The level of ERK1/2 phosphorylation in both types of AT-MSCs 
was clearly reduced by PD98059 treatment, whereas the treatment did not 
affect the phosphorylation of AKT at serine 473 (Fig. 8A).  
EGR-1 expression was almost completely repressed by PD98059 in 
both types of AT-MSCs under normoxic conditions (Fig. 8B). Interestingly, 
however, the persistent expression of EGR-1 was detected in the PD98059-
treated dAT-MSCs under hypoxic conditions, suggesting that an additional 
upstream signal is involved in the EGR-1 induction in dAT-MSCs under 
hypoxic conditions (Fig. 8B). These results indicate that the increased EGR-1 
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expression that is observed in dAT-MSCs under hypoxic conditions is 
mediated by at least two distinct mechanisms: ERK1/2 signaling activation 
and direct transcriptional activation by HIF-1α.  
To evaluate the relative contribution of the ERK1/2 pathway in dAT-
MSCs on the expression of the EGR-1 target genes, the effect of PD98059 on 
the expression of the EGR-1 target genes was examined by a quantitative 
RT-PCR (Fig. 9). In the presence of PD98059, the mRNA levels of all of the 
cytokines and adhesion molecules that were examined were reduced in dAT-
MSCs to levels that were comparable to those in nAT-MSCs (Fig. 9). 
 As a result of the remarkable changes of IL6 and Cyr61 in mRNA 
levels, I analyzed these two proteins by Western blot and ELISA assay (Fig. 
10). These data confirmed that the protein level of IL6 and Cyr61 were 
remarkably increased in dAT-MSCs compared to nAT-MSC. Consistent with 
the result in mRNA expression, the expressions of IL6 and Cyr61 were 
significantly decreased in dAT-MSCs the presence of the inhibitor (Fig. 10). 
Thus, these data suggest that the ERK1/2 pathway is the major upstream 
signal for the expression of EGR-1 in dAT-MSCs. On the other hand, the 
effect of HIF-1α on EGR-1 expression is minor, but is specifically observed in 
AT-MSCs under diabetic conditions. 
 
2.3.5.! The constitutive activation of EGR-1 is responsible for the 
impaired wound repair activity of dAT-MSCs  
My findings showed that dAT-MSCs were less effective for improving 
wound repair in the ischemic flap and that EGR-1 expression was 
constitutively activated in dAT-MSCs. In order to provide direct evidence of 
the involvement of EGR-1 in the impaired wound healing activity of dAT-
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MSCs, EGR-1 expression was knocked down by shRNA. As shown in 
Figure 11A, EGR-1 expression was reduced by shRNA in dAT-MSCs at both 
the mRNA and the protein level (Fig. 11A). In accordance with the reduction 
in EGR-1, the expression of Cyr61 at protein level was abolished in the 
knockdown EGR-1-dAT-MSCs under both normoxic and hypoxic conditions 
(Fig. 11B).  
In addition, the expression levels of PTEN and GGPS1, three 
cytokines (bFGF, TGF-β, and IL-6), and three adhesion molecules (Cyr61, 
Col4, and Inαv) were significantly decreased under hypoxic conditions (Fig. 
11C and Fig. 12). In accordance to the result in Figure 9, the gene 
expression levels of TGF-β, Col4, and Inαv were not affected by PD98059 in 
dAT-MSCs under normoxic conditions (Fig. 9). The mRNA level of PTEN, 
TGF-β, Col4, and Inαv was not significantly reduced by shEGR-1 under 
normoxic conditions in dAT-MSCs, whereas the expression levels of the 
other genes were comparable in both types of AT-MSCs under normoxic 
conditions (Fig. 12). These data suggest that the role of EGR-1 in the 
regulation of these genes was restricted under normoxic conditions.  
 
2.3.6.!The reduced expression of EGR-1 in dAT-MSCs promotes wound 
repair activity 
  In order to examine whether the repression of EGR-1 by shRNA 
restored the ability to improve wound healing in dAT-MSCs, the wound 
healing activity of EGR-1-deficient dAT-MSCs was examined using the 
mouse skin flap model (Fig. 13A). I found that the knock-down of EGR-1 in 
dAT-MSCs significantly reduced the necrotic surface area of the ischemic 
flap.  
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The H&E staining of the wound section showed that the epidermis of 
mice injected with EGR-1-deficient dAT-MSCs was thicker than that in mice 
that were injected with dAT-MSCs (Fig. 13B). Moreover, neovascularization 
was significantly increased, whereas the infiltration of CD45-positive cells 
was reduced in the EGR-1-deficient dAT-MSCs in comparison to the 
controls (Fig. 13BD). Collectively, these data suggest that the constitutive 
activation of EGR-1 in dAT-MSCs is responsible for the impaired wound 
repairing activity. dAT-MSCs expressed excessive adhesion molecules and 
pro-inflammatory cytokine IL-6, which may cause prolonged inflammation 
phase in wound healing process (Fig. 14). 
 
2.4. Discussion 
I found the same characteristics, gene and protein expression 
patterns of dAT-MSCs from three diabetic donors who have similar 
backgrounds (gender, HbA1c, period, and treatment of T2DM). To have a 
good comparison between nAT-MSCs and dAT-MSCs, I also examined 
nAT-MSCs from three non-diabetic donors who also have comparable range 
of age and gender (Table 1). 
My work showed that EGR-1 is constitutively activated in AT-MSCs 
derived from T2DM patients. I focused on this molecule because its 
overexpression in adipocytes plays a central role in insulin resistance in 
T2DM patients [26,27]. The overexpression of EGR-1 leads to the activation 
of two critical target genes (PTEN and GGPS1) in adipocytes. While GGPPS 
activates MAPK/ERK1/2 signaling, PTEN impairs PI3K/Akt signaling, thereby 
reducing signals from insulin receptors in T2DM adipocytes [26,27]. My data 
showed the increased expression of PTEN and GGPS1 and the 
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phosphorylation of IRS-1 at serine 636/639 in dAT-MSCs, suggesting an early 
manifestation of insulin resistance at the stem cell level under diabetic 
conditions. 
My data showed that dAT-MSCs appeared to aggregate exclusively 
under hypoxic conditions in vitro, and that these cells were less effective for 
improving wound healing in the mouse skin flap model. The repression of 
EGR-1 by shRNA restored the ability of dAT-MSCs to improve wound healing, 
suggesting that EGR-1 is responsible for the impaired wound repair ability of 
dAT-MSCs (Fig. 13). Notably, the reduction of EGR-1 in dAT-MSCs 
significantly improved neovascularization at wound site on the ischemic flap 
(Fig. 13C).  
Macro/microangiopathy in T2DM patients is characterized by the 
increased expression of a variety of growth factors and adhesion molecules 
[3,7]. For instance, bFGF and TGF-β are known to increase vascular 
permeability and coagulation, which leads to blood flow abnormalities in 
patients with diabetic angiopathy [7,51]. Cyr61, Col4, and Inαv are the 
markers of microangiopathy in diabetic patients [55–58]. In agreement with 
previous reports, my results showed the upregulation of these growth factors 
and adhesion molecules in dAT-MSCs at mRNA level (Fig. 6B, 6C).  
Importantly, Cyr61 is an extracellular matrix protein and plays an 
important role as an angiogenic mediator. It has been reported that Cyr61 
participates in the pathogenesis of proliferative diabetic retinopathy and 
rheumatoid arthritis [55,59]. In this study, the mRNA levels of Cyr61 was 
significantly decreased in both PD98059-treated dAT-MSCs and in EGR-1 
knock-down dAT-MSCs (Fig. 9B, 12A). In addition, the expression of Cyr61 at 
protein level was diminished in dAT-MSCs treated with inhibitor or shEGR-1 
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(Fig. 10A, 11B).  
IL-6 has been shown to play critical roles in T2DM, obesity and 
cardiovascular diseases [60,61]. The circulating levels of plasma IL-6 are 
increased in T2DM patients who are treated with insulin [60]. Excessive 
amounts of IL-6 have been shown to prolong the inflammatory response in 
injuries and to delay the wound healing process [62,63]. In fact, the 
expression of IL-6 in dAT-MSCs was 25-fold higher at mRNA level and 4-fold 
increase at protein level than in nAT-MSCs (Fig. 6A). The expression of IL6 
was downregulated in the presence of PD98059 at mRNA (Fig. 9B) and 
protein levels (Fig. 10B). Thus, it is likely that IL-6 plays a key role in the 
impairment of the wound healing ability of dAT-MSCs.  
Further studies are required to determine the precise roles of the 
individual cytokines and adhesion molecules that are highly expressed in 
dAT-MSCs under normal or diabetic conditions in vivo (db/db mice). 
The increased expression of EGR-1 has also been reported in patients 
with scleroderma, an autoimmune disease that affects collagen [31]. The 
induction of EGR-1 by TGF-β plays an important role in the promotion of 
fibrosis in the fibroblasts of scleroderma patients [54]. Interestingly, in EGR-1 
null mice, the impaired healing of cutaneous wounds and fibroblast-specific 
EGR-1 overexpression under the control of the Col1a2 promoter resulted in 
the robust healing of incisional wounds [38]. In contrast, the aberrant and 
persistent expression of EGR-1 in peripheral tissue promoted scleroderma 
and pulmonary fibrosis in a murine model [54,55]. Taken together with my 
present data, these results suggest that EGR-1 plays a dual role in wound 
healing which is dependent on the cellular context. Given that fibroblasts are 
descendants of MSCs, the biological function of EGR-1 might change with 
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cellular differentiation. Thus, the rigorous regulation of EGR-1 expression 
would be important to the appropriate control of wound healing.  
Although several studies have suggested EGR-1 to be a hypoxia-
inducible gene, the elevated expression of EGR-1 in dAT-MSCs was 
constitutively observed under both normoxic and hypoxic conditions (Fig. 5A, 
5B). Since EGR-1 expression was clearly diminished by PD98059, an inhibitor 
of MAPK/ERK kinase ERK1/2 (Fig. 8B), MAPK signaling is likely to be the 
major upstream regulator of EGR-1 in dAT-MSCs.  In fact, phosphorylated 
ERK activates ELK-1 binding to serum response elements (SRE) in EGR-1 
promoter [53], indicating MAPK signaling pathway promotes mutual activation 
of EGR-1 expression in both AT-MSCs.  
Of note, the residual expression of EGR-1 was found in dAT-MSCs 
under hypoxic conditions (Fig. 8B), suggesting the existence of an additional 
pathway of EGR-1 regulation in dAT-MSCs under hypoxic conditions. HIF-1α 
bound directly to the EGR-1 promoter in dAT-MSCs examined by ChIP assay, 
suggesting that EGR-1 expression is regulated by both MAPK signaling and 
HIF-1α in dAT-MSCs. This regulatory pathway of EGR-1 by HIF-1α is 
relatively minor; however, under certain pathological conditions, it might play a 
specific role in T2DM patients.!!
Interestingly, although the EGR-1 protein levels were similar under 
normoxic and hypoxic conditions, EGR-1 shRNA treatment resulted in the 
reduction of a group of genes (TGF-β, Col4, and Inαv) under hypoxic, but not 
normoxic conditions (Fig. 9). Consistently, PD98059 only affected the 
expression of these genes under hypoxic conditions (Fig. 9). These results 
suggest that the expression of these genes is only regulated by EGR-1 under 
hypoxic conditions. The molecular mechanism underlying the functional 
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differences of EGR-1 under normoxic and hypoxic conditions remains to be 
elucidated.  
In conclusion, the present study demonstrates that the expression of 
EGR-1 was upregulated in dAT-MSCs through two different pathways. The 
main regulatory pathway is the MAPK/ERK pathway, which is independent of 
oxygen tension. The other regulatory pathway is mediated by HIF-1α through 
the direct transcriptional activation at the promoter region of the EGR1 gene. 
The latter is observed under hypoxic conditions in dAT-MSCs but not in nAT-
MSCs. My data demonstrate that a high level of EGR-1 is responsible for the 
impaired wound healing effect of dAT-MSCs. Thus, the control of EGR-1 
expression by the manipulation of the upstream MAPK/ERK signaling and HIF 
factors could be a new therapeutic target for stem cell therapy in T2DM 
patients with chronic wounds and tissue ischemia. 
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Chapter III. Microvesicles enhance the mobility of human 
diabetic adipose tissue-derived mesenchymal stem cells in 
vitro and improve wound healing in vivo 
 
3.1. Introduction 
3.1.1. Mesenchymal stem cells and microvesicles  
AT-MSCs secrete supportive soluble factors enhance cellular 
communication, allowing information delivery from one cell to another by a 
paracrine signaling, which is prerequisite of a rapid cellular and tissue 
response [28–30]. Recent studies suggested that cellular communication 
has also involved intercellular transfer of extracellular vesicles including 
exosomes and microvesicles (MVs), which released by cells during 
apoptosis or stimulation [64,65]. Healthy cells can bud MVs directly from 
their plasma membrane (100 – 1000 nm in diameter), which contain a lot of 
genetic information from secreting cells [64–66]. MSCs release MVs 
associated with cell-to-cell communication and the ability of switching the 
cell function of recipient cells [66,67].  
 
3.1.2. Mesenchymal stem cells-derived microvesicles (MSC-MVs) are 
considered as a potential therapeutic tool in clinical application 
MSC-MVs deliver bioactive cargo and specific microRNAs, mRNAs, 
and proteins to recipient cells to induce phenotypic, epigenetic, and functional 
changes in the recipient cells that promote the activation of regenerative 
programs in somatic cells such as hepatic cells, fibroblasts, tubular cells, and 
endothelial cells [68–71]. Previous reports in preclinical investigation of MSC-
MVs mainly emphasized their therapeutic potential in improving the function of 
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renal tubular cells, modulating T cell response in patients with type 1 diabetes 
mellitus, reducing severe pneumonia in mice, enhancing survival in a lethal 
model of acute kidney injury, and inhibiting tumor cell growth [68–72].   
Most reports have characterized healthy AT-MSCs, which can secrete 
efficient soluble factors and MVs, supporting tissue repair and regeneration 
[35,36,67]. By contrast, I demonstrated that dAT-MSCs have impaired 
function in wound healing ability due to the up-regulation of adhesion 
molecules and prolonged inflammatory stage. Thus, the aim of this work is to 
investigate how to improve the function of dAT-MSCs in wound healing and 
examine the effect of human AT-MSC-derived MVs on dAT-MSCs. 
 
3.2. Materials and methods 
 
3.2.1. The isolation of AT-MSCs 
 AT-MSCs were isolated using previous described protocol. Briefly, 
human adipose tissue was obtained after obtaining informed consent from 
diabetic patients (n=5, HbA1c > 7.0, long-term treatment) and non-diabetic 
donors (n=5, male, age=59 ± 10 years), who were undergoing procedures in 
the Department of Cardiovascular Surgery, University of Tsukuba Hospital, 
Tsukuba, Japan. All AT-MSCs used for the experiments of this study were at 
passage 5-8. 
 
3.2.2. Microvesicles isolation and transfection 
MVs were obtained from the supernatant of nAT-MSCs following a 
previous protocol [73]. Briefly, the medium of subconfluent nAT-MSCs was 
changed to Dulbecco’s modified eagle medium (DMEM) no phenol red 
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(Gibco, NY, USA) containing 0.25% bovine albumin fraction (Sigma-Aldrich, 
Louis, MO, USA). After 24 h, the supernatants were collected and centrifuged 
at 1000xg for 20 min. Cell-free supernatants were ultracentrifuged at 
100,000xg for 70 min at 4℃, washed with phosphate-buffer saline (PBS), and 
underwent second ultracentrifuge at the same conditions. MSC-surface 
markers on MVs were sorted and analyzed using a MoFlo system (MoFlo 
XDP; Beckman Coulter, CA, USA) for PE-labeled anti-CD105 (323206, 
BioLegend, CA, USA), FITC-labeled anti-CD90 (328107, BioLegend), and 
allophycocyanin (APC)-labeled anti-CD45 (555485, BD Biosciences, CA, 
USA). The protein content of MVs was quantified using the Bradford method 
(BioRad, CA, USA). 
 
3.2.3. PKH26-labelled microvesicles 
The PKH26 red fluorescent cell linker kit for general cell membrane 
labeling (PKH26GL-1KT, 100M0612, Sigma-Aldrich) was used to stain nAT-
MSC-derived MVs according to the manufacturer’s protocol. The labeled MVs 
were incubated with dAT-MSCs in culture (7.5 µg per 500,000 cells). The 
efficiency of MV-transfected cells was determined by a FACS analysis 
according to the red fluorescence signal after 12 h of MV transfection. 
 
3.2.4. In vitro wound healing assay (scratch assay) 
An in vitro scratch assay was performed according to a protocol 
described previously [74]. Briefly, nAT-MSCs or dAT-MSCs were seeded at 
a density of 3 × 105 cells per 4-well plates. After 24 h, confluent monolayers 
were treated with mitomycin C (10 µg/mL) for 3 h to eliminate the possibility 
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of cell proliferation [75]. A scratch was created with a p1000 pipet (1 mm 
width) and cells were non-treated or treated with MVs in the culture medium. 
Images of the scratch were captured at 0 h and 16 h. The analysis of the 
scratch area was performed using the WimScratch software program 
(https://mywim.wimasis.com). The data presented are the average of ten 
measurements from five independent scratch areas. 
 
3.2.5.!RT-PCR for miRNAs  
The quantification of miRNAs using the TaqMan miRNA assays 
protocol (Applied Biosystems, CA, USA) was performed by two-step RT-
PCR following the manufacturer’s protocol. Briefly, the RT step was 
performed using the TaqMan miRNA reverse transcription kit (1502183, 
Applied Biosystems) and the PCR step was performed using TaqMan 
universal PCR master mix II, with UNG (1503029, Applied Biosystems) . The 
primers for miRNAs include hsa-miR-150 (P140506-007 F11), hsa-miR-29c 
(P141106-000 G07), and RNU48 (P141013-007 E07) (Applied Biosystems). 
 
3.2.6. Quantitative RT-PCR 
To examine the gene expression, RNA was extracted using an 
RNeasy mini kit (Qiagen, Valencia, CA). Total RNA (1 µg) was reverse 
transcribed using an RT-PCR kit (TOYOBO, Japan). cDNA was analyzed 
using a GeneAmp 7500Fast Real-Time PCR System (Applied Biosystems) 
using CYBR green reagent (TOYOBO). The expression levels of the target 
! 32 
genes were analyzed using the ΔΔCt method. The sequences of the primer 
sets used for the PCR reactions were in Table 1. 
3.2.7. Animal studies 
Female C57BL/6 mice were purchased from Charles River Japan, 
Inc. All of the mice were maintained on a 12-h light/dark cycle in the Animal 
Research Center of the University of Tsukuba. All protocols of the animal 
experiments were approved by the Animal Care Committee of the University 
of Tsukuba. The mouse skin flap model was performed as described 
previously. The mice were divided into 4 groups: PBS (n=5), nAT-MSC 
(n=10), dAT-MSC (n=10), and MV-treated dAT-MSCs (n=10). 
 
3.2.8. Histological analysis 
The tissue structure was stained by hematoxylin and eosin 
counterstain. Inflammatory cells in the ischemic tissue were examined by 
immunohistochemical staining with PE-labeled anti-CD45 (30F11, BD 
Pharmingen, USA). The number of CD45-positive cells was counted in each 
field. The presented data are the average of ten fields per section. 
 
3.2.9. Statistical analysis 
Student’s t-test and one-way ANOVA (Bonferroni post-hoc test; SPSS® 
software, IBM Corp.) were used to determine the significant difference 
between two and more experimental groups, respectively. A P-value < 0.05 
was considered to be statistically significanct. The data are presented as the 
mean ± standard deviation (SD). 
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3.3. Results 
 
3.3.1.! The impairment of dAT-MSCs in gene expression and migration 
ability in vitro  
I previously demonstrated that the wound healing ability of human 
dAT-MSCs was impaired in the ischemic flap mouse model because of 
increasing numbers of adhesion molecules and a prolonged inflammation 
stage. In this study, I investigated the migration ability and migratory factors 
expressed in dAT-MSCs compared with those in nAT-MSCs. It has been 
reported that migration factors (SDF-1, CXCR4), survival factor (CXCR7), 
early response inflammatory cytokine (CCL2) and angiogenic factor 
(ANGPTL4) are the main soluble factors secreted from MSCs that contribute 
to enhanced cell proliferation, migration and survival of tumor cells and play 
important roles in augmenting acute and chronic wound healing [36,76,77]. 
Thus, I investigated these factors and found that SDF-1, CXCR4, CXCR7, 
CCL2, and ANGPL4 were significantly down-regulated in dAT-MSCs 
compared to nAT-MSCs (SDF-1, 1.9 ± 0.3 fold decrease, P < 0.05, n=3 in 
each; CXCR4, 2.2 ± 0.4 fold decrease, P < 0.05, n=3 in each; CXCR7, 3.5 ± 
0.3 fold decrease, P < 0.01, n=3 in each; CCL2, 3.0 ± 0.9 fold decrease, P < 
0.05, n=3 in each; ANGPL4, 2.0 ± 0.5 fold decrease, P < 0.05, n=3 in each) 
(Fig. 15).  
I speculated that the reduction of these factors in dAT-MSCs might 
affect the impairment of the migration rate of dAT-MSCs. Therefore, I 
performed the in vitro scratch assay, a suitable method for studying the 
effects of cell-matrix and cell-cell interactions, which mimics cell migration 
during wound healing in vivo. The results showed that the percentage of 
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uncovered wound areas at 16 h of dAT-MSCs was remarkably higher than 
that of nAT-MSCs (wound area: dAT-MSCs, 19.7% ± 4.5% vs. nAT-MSCs, 
10.1% ± 5.1%; P < 0.05, n=10 in each) (Fig. 16), indicating that dAT-MSCs 
had an impaired ability to migrate to the wound site, possibly due to defect in 
the secretion of effective factors that support this process. 
 
3.3.2. nAT-MSC-derived MVs modify the expression of miRNAs and 
mRNAs in dAT-MSCs 
MVs have been isolated from many sources of adult MSCs, such as 
the bone marrow and Wharton’s jelly-MSCs [67,78]. Here, I isolated MVs 
from human nAT-MSCs (nMVs). I characterized nMV-surface markers by 
FACS and showed that nMVs expressed CD105 and CD90, but not CD45 
(Fig. 17A). To examine and quantify the efficiency of nMV internalization into 
dAT-MSCs, I labeled nMVs with PKH26 red fluorescence [73]. After 12 h of 
transfection, the internalization of nMVs into dAT-MSCs was determined by 
PKH26 red fluorescence captured by microscopy (Fig. 17B) and quantified 
by FACS analysis (Fig. 17C), resulting in the generation of dAT-MSC-
transfected nMVs.  
MVs contain many miRNAs, which are non-coding single-stranded 
RNA of approximately 22 nucleotides involved in mRNA silencing and post-
transcriptional regulation of the gene expression [67]. I found that miR29c and 
miR150 were highly expressed in dAT-MSCs compared with nAT-MSCs (P < 
0.01, n=3 in each) (Fig. 18A). Interestingly, the expression of miR29c and 
miR150 was significantly down-regulated in nMV-treated dAT-MSCs 
compared with non-treated dAT-MSCs (P < 0.01, n=3 in each), suggesting 
that the expression of miRNA29c and miR150 were possibly alternated in 
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response to endogenous modification after MV internalization. 
Moreover, I found that the expression of SDF-1, CXCR4, CXCR7, 
CCL2, and ANGPTL4 in nMV-treated dAT-MSCs was significantly elevated 
compared with control dAT-MSCs (SDF-1, 2.0 ± 0.4 fold increase, P < 0.05, 
n=3 in each; CXCR4, 2.1 ± 0.5 fold increase, P < 0.05, n=3 in each; CXCR7, 
2.4 ± 0.6 fold increase, P < 0.05, n=3 in each; CCL2, 2.7 ± 0.6 fold increase, 
P < 0.05, n=3 in each; and ANGPL4, 3.2 ± 0.2 fold increase, P < 0.01, n=3 in 
each). Notably, the mRNA expressions of these factors in nMV-treated dAT-
MSCs were at similar levels to those in nAT-MSCs (Fig. 18B, 18C). 
 
3.3.3. nMVs enhance the wound healing ability of dAT-MSCs in vitro. 
Since I found the up-regulation of soluble factors involved in the wound 
healing process in nMV-treated dAT-MSCs (Fig. 18B, 18C), I next examined 
the ability of these cells in wound healing in vitro. My data showed that the 
percentage of uncovered wound areas at 16 h of nMV-treated dAT-MSCs was 
significantly decreased compared with that of dAT-MSCs (wound area: nMV-
treated dAT-MSCs, 9.3% ± 5.0% vs. dAT-MSCs, 19.8% ± 4.8%, P < 0.01, 
n=10 in each) (Fig. 19A, 19B), suggesting the migration ability of dAT-MSCs 
was enhanced after nMV internalization. Importantly, the migration ability of 
nMV-treated dAT-MSCs was similar to that of nAT-MSCs (Fig. 19A, 19B). 
Collectively, nMVs were able to enhance the migration rate of dAT-MSCs. 
 
3.3.4.! MV-treated dAT-MSCs improve the wound healing ability in the 
flap mouse model 
I hypothesized that nMV-treated dAT-MSCs had increased migration 
and chemotaxis, supporting their regenerative activity, in ischemic tissue in 
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vivo. To test this hypothesis, the wound healing activity of AT-MSCs was 
examined using ischemic moue flap models. After one week of surgery and 
a subcutaneous injection of AT-MSCs, the necrotic area was significantly 
reduced in mice injected with nMV-treated dAT-MSCs compared with mice 
injected with non–treated dAT-MSCs (necrotic area: nMV-treated dAT-
MSCs, 15.8% ± 3.0% vs. dAT-MSCs, 37.1% ± 8.0%, P < 0.01, n=10 in each) 
(Fig. 20A, 20B). Notably, the percentage of the necrotic area was not 
significant different between nAT-MSC and nMV-treated dAT-MSC injected 
mice (necrotic area: nAT-MSCs, 17.6% ± 5.0% vs. nMV-treated dAT-MSCs, 
15.8% ± 3.0%, P < 0.01, n=10 in each) (Fig. 20B).  
H&E staining showed recovery of the wound area and epidermis in 
mice injected with nMV-treated dAT-MSCs as well as nAT-MSC, whereas 
the wound area and epidermis were not recovered in mice injected with PBS 
or dAT-MSCs (Fig. 21A). Mice injected with nMV-treated dAT-MSCs or nAT-
MSCs showed significantly increased frequencies of CD45-positive cells at 
the wound sites compared to mice injected with dAT-MSCs (P < 0.05, n=10) 
(Fig. 21A, 21B), suggesting that early inflammation occurred in response to 
tissue injury at day 3 of the wound healing process. These findings suggest 
that nMV-treated dAT-MSCs improved wound healing ability in flap mouse 
model. 
 
3.4. Discussion 
AT-MSCs have been shown to be efficacious in the treatment of 
wounds, including chronic wound [28]. However, in this study, the down-
regulation of genes related to cell migration and chemotaxis was found in 
dAT-MSCs from five diabetic donors compared to those of nAT-MSCs from 
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five non-diabetic donors (Table 1), indicated reduction of the dAT-MSC 
function in stimulating cell migration, survival, and angiogenesis in target 
stromal cells. I also demonstrated that dAT-MSCs have impaired cell 
migration in vitro via the scratch assay (Fig. 16). Previous work has 
demonstrated that MVs derived from Alde-low endothelial progenitor cells 
(EPCs) can improve the migration and angiogenesis of non-function Alde-
high EPCs [73]. I thus hypothesized that MVs from nAT-MSCs can improve 
the function of dAT-MSCs in wound healing.  
MVs are released from various cell types including platelets, 
endothelial cells, erythrocytes, monocytes, lymphocytes, and leucocytes 
upon activation or apoptosis [64,65]. MVs derived from EPCs and MSCs 
improve the migration, survival, and angiogenesis of non-functioning EPCs, 
epithelial cells, inflammatory cells, and diabetic chronic wound fibroblasts 
[68–73]. MVs have the ability to act as autocrine and paracrine effectors in 
cell-to-cell communication due to the composition of biological materials 
from their parental cells, which includes bioactive lipids, integrins, cytokines, 
enzymes, mRNA, miRNAs, and transcription factors [64–67].  
I herein demonstrated that MVs alter the expression of miR29c and 
miR150 in dAT-MSCs (Fig. 18A). It has been reported that miR29c and 
miR150 are highly up-regulated in skeletal muscles of rat type 2 diabetes 
mellitus by a microarray analysis [79]. On the other hand, the inhibition of 
miR29c can improve insulin sensitivity, while the knockdown of miR150 
augments the CXCR4 expression and mobilization of bone marrow-derived 
mononuclear cells (BM-MNCs) [79–81]. In agreement with these reports, I 
found that miR29c and miR150 were highly expressed in dAT-MSCs and 
down-regulated after transfecting nMVs into dAT-MSCs (Fig. 18A). Previous 
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report identified that the expression of miR-150 was down-regulated in BM-
MNCs in response to myocardial ischemia with simultaneous induction of the 
CXCR4 protein expression [81]. Willeit et al. (2013) also demonstrated that 
plasma levels of miRNAs, such as miR-126, miR-150, miR-191, and miR-223 
were decreased in response to antiplatelet therapy [82], Therefore, miR29c 
and miR150 may have been down-regulated in nMV-treated dAT-MSCs in 
response to interactions within the microenvironment, leading to endogenous 
modification and tissue regeneration.  
nAT-MSC-derived MVs have a beneficial effect on dAT-MSCs in that 
they can improve the expression of genes related to cell migration (SDF-
1/CXCR4), survival (CXCR7), inflammation (CCL2), and angiogenesis 
(ANGPTL4) (Fig. 18B, 18C). Homing of MSCs to injured tissues is dependent 
on their ability to migrate and interact with the local microenvironment. The 
interaction of SDF-1/CXCR4 plays a crucial role in stem cell mobilization and 
improves neovascularization in vivo [77].  
It has been reported that CXCR7, a survival factor, is highly expressed 
in AT-MSCs and promotes glioblastoma multiforme (GBM) proliferation. 
Knockdown of CXCR7 in AT-MSCs promoted tumor cell apoptosis due to the 
inhibition of the SDF-1/CXCR7 pathway in GBM [33]. CCL2 plays an 
important role in the early inflammation response in ischemic tissues [36], 
while ANGPTL4 is a crucial angiogenic factor that contributes to diabetic 
wound healing [76]. The triggering of these factors by nMVs may induce cell 
migration in wound healing in vitro (Fig. 19), suggesting that nMVs play a key 
role in intercellular modification and represent a delivery system for effective 
transfer of biological information to dAT-MSCs. 
The wound healing capacity in the flap mouse model was impaired in 
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dAT-MSCs and enhanced in nMV-treated dAT-MSCs. The necrotic area was 
reduced in nMV-treated dAT-MSCs due to the recovery in the wound and 
epidermis area and the recruitment of inflammatory cells, suggesting 
modification of the dAT-MSC function in wound healing. Although I found the 
great potential of nMVs and its influence on dAT-MSCs, further studies are 
necessary to elucidate the mechanisms by which nMVs are able to modify the 
miRNA expression and manipulate gene expression in dAT-MSCs. 
In conclusion, this study demonstrated that nAT-MSC-derived MVs 
have the ability to alter the expression of miRNA29c and miR150 and up-
regulate the gene expression of SDF-1, CXCR4, CXCR7, CCL2, and 
ANGPTL4, which are known to play crucial roles in acute and chronic 
wounding. The modification of nMV-treated dAT-MSCs enhances their 
mobility to the wound site both in vitro and in vivo, thereby suggesting a new 
therapeutic target for improving the dAT-MSC function before application in 
clinical treatment. 
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Chapter IV. Conclusions and perspectives 
 
4.1. Conclusions 
In this study, dAT-MSCs have potential to differentiate into 
osteoblasts, adipocytes, and chondrocytes as well as expressing stem cell 
surface markers. Interestingly, the adipogenic differentiation was higher in 
dAT-MSCs than in nAT-MSCs. The expression of activated leukocyte cell 
adhesion molecule CD166/ALCAM is dramatically increased in dAT-MSCs 
compared with nAT-MSCs by FACS analysis, suggesting that this molecule 
may associate with the increase of adiposity and inflammation related with 
T2DM and its complication. 
In dAT-MSCs, EGR-1 significantly elevated the expression of many 
target genes correlated with insulin resistance, adhesive phenomenon in vitro, 
and impairment of wound healing activity in vivo. EGR-1 was a key regulator, 
which was upregulated by ERK1/2 signaling pathway and HIF-1a in dAT-
MSCs under normoxic and hypoxic conditions. The ERK1/2 inhibitor 
(PD98059) and knock-down of EGR-1 expression were useful to modulate the 
expression EGR-1 target genes and improved wound healing capacity of dAT-
MSCs. 
Microvesicles derived from nAT-MSCs (nMVs) expressed MSC surface 
markers and easy internalized into dAT-MSCs. nMVs alternated miRNA 
expression and modification gene expressions related to migration and 
chemotaxis in dAT-MSCs. By these effects, nMVs induced cell migration 
ability of dAT-MSCs in vitro and improved wound healing ability in vivo. 
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4.2. Perspectives 
In perspective, EGR-1 may be an ideal therapeutic target for improving 
the function of dAT-MSCs before their therapeutic application. Interrupting the 
expression of EGR-1 in dAT-MSCs may be a useful treatment for chronic 
wounds in diabetic patients. The control of EGR-1 expression by the 
manipulation of the upstream MAPK/ERK signaling and HIF factors could be a 
new therapeutic target for stem cell therapy in T2DM patients with chronic 
wounds and tissue ischemia. 
This study also demonstrates a promising opportunity to modify the 
function of dAT-MSCs for therapeutic stem cell application in diabetic patients. 
nMVs play a key role in cell communication, intercellular modification, and 
represent a delivery system for effective transfer of biological information to 
dAT-MSCs. It is a new therapeutic target for improving the dAT-MSC function 
before application in clinical treatment. 
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Tables 
 
Table 1. The background information of adipose tissues from diabetic and 
non-diabetic donors   
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Table 2. The primers used for quantitative polymerase chain reaction 
 
Function Gene Primer Sequence 
Internal 
control 
β-actin 
5’-primer 
3’-primer 
GTGCGTGACATTAAGGAGAAGCTGTGC 
GTACTTGCGCTCAGGAGGAGCAATGAT 
Transcription 
factors 
EGR-1 
 
5’-primer 
3’-primer 
AGTCTTTTCCTGACATCTCTCTGAA 
ACTAGGCCACTGACCAAGCTGAA 
Migration 
factors 
SDF-1 
5’-primer 
3’-primer 
AACGCCAAGGTCGTGGTCGTGCTGG 
CTACAATCTGAAGGGCACAGTTTGG 
CXCR4 
5’-primer 
3’-primer 
CTGTGACCGCTTCTAC CCCAATGACTT 
CCAAGGAAAGCATAGAGGATGGGGTTC 
CXCR7 
5’-primer 
3’-primer 
TAAATATATGCCAGTCTTGGCTGA 
TTACAAAGCAGTTTTCGTTCCATA 
Angiogenic 
factors 
TGF-β 
5’-primer 
3’-primer 
AGAGCTCCGAGAAGCGGTACCTGAACCC 
GTTGATGTCCACTTGCAGTGTGTTATCC 
bFGF 
5’-primer 
3’-primer 
AGAGCGACCCTCACATCAAGCTACAAC 
ATAGCTTTCTGCCCAGGTCCTGTTTTG 
ANGPTL4 
5’-primer 
3’-primer 
CTCAAGGCTCAGAACAGCAGGATCC 
CTTGGCCACCTCATGGTCTAGGTGC 
Adhesion 
molecules 
Cyr61 
5’-primer 
3’-primer 
TGGGTCTGTGACGAGGATAGTATCAAGG 
CTTGTAAAGGGTTGTATCGGATGCGAGG 
Col4 
5’-primer 
3’-primer 
AGGGCCAGCCTGGCCTGCCAGGACTTCC 
TCACCCTTAGAGCCTGTGATTCCTGGAG 
Inav 
5’-primer 
3’-primer 
ATACGACCCCAATGTTTACAGCATCAAG 
GCCAGTAAAATTGTATAAGGAGGACATG 
Inflammatory  
cytokine 
IL-6 
5’-primer 
3’-primer 
ACAAGAGTAACATGTGTGAAAGCAG 
TATACCTCAAACTCCAAAAGACCAG 
CCL2 
5’-primer 
3’-primer 
ATGAAAGTCTCTGCCGCCCTTCTGTG 
TCAAGTCTTCGGAGTTTGGGTTTGCTT 
Adipogenic 
markers 
PPARγ2 
5’-primer 
3’-primer 
GCCAAGGCTTCATGACAAGGGAGTTTC 
CACGTGTTCCGTGACAATCTGTCTGAG 
Adiponectin 5’-primer CCTGGTGAGAAGGGTGAGAAAGGAGATCC 
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3’-primer TGTGATGTGGTAGGCAAAGTAGTACAGCC 
Osteogenic 
markers 
Runx2 
5’-primer 
3’-primer 
CAGATGGGACTGTGGTTACTGTCATGG 
CCTAAATCACTGAGGCGGTCAGAGAAC 
ALP 
5’-primer 
3’-primer 
ACGTGGCTAAGAATGTCATC 
CTGGTAGGCGATGTCCTTA 
Mediators of 
insulin 
resistance 
 
PTEN 
5’-primer 
3’-primer 
TTG GCG GTG TCA TAA TGT CT 
GCA GAA AGA CTT GAA GGC GTA 
GGPS1 
5’-primer 
3’-primer 
ACTGTTTGGATTAGCAGTAGGTCTC 
GGAGTGTAGATTAGCATAATCATCC 
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Figures and Legends 
 
Fig. 1. Differentiation potential of dAT-MSCs in comparison of nAT-MSCs. A, 
Differentiated cells were recognized on day 21 using Alizarin Red staining, which 
indicated the calcification of the surface of osteoblasts (red). Oil Red O staining 
indicated the lipid accumulation of adipocytes (red); hematoxylin and eosin staining 
was performed as a control. Toluidine blue staining indicated cartilage proteoglycan 
and glycosaminoglycan (purple). B, Absorbance was measured at 482 nm and 490 
nm for Alizarin Red and Oil Red O staining, respectively. In the Oil Red O staining 
of dAT-MSCs, absorbance was significantly higher than that in nAT-MSCs. C, The 
expression levels of differentiated master genes Runx2, ALP, PPARγ2, and 
adiponectin were examined by a qRT-PCR and normalized to β-actin on days 0 and 
7 of osteogenic and adipogenic induction. The white and black bars indicate nAT-
MSCs and dAT-MSCs, respectively. The data represent the average of three 
independent experiments (mean ± SD); *, P < 0.05; **, P < 0.01.  
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Fig. 2. nAT-MSCs and dAT-MSCs were analyzed and sorted by a FACS Vantage 
SE to determine the expressions of HLA-ABC, CD90, CD13, CD166, CD105, 
CD73, HLA-DR, CD31, CD14, CD45, and CD34 (line peaks) in comparison to 
isotype controls (black peaks)  
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Fig. 3. Cell proliferation of nAT-MSCs and dAT-MSCs under normoxic and 
hypoxic conditions. A, The number of cells was counted every 24 h using trypan 
blue exclusion over 10 days under normoxic (20% O2) or hypoxic (5% O2) 
conditions. Abnormal cell adhesion was observed in dAT-MSCs under hypoxic 
conditions on day 7. The precise number of cells could not counted because the 
cells adhered together too tightly. The average doubling time was 32.5 ± 2 h under 
normoxic conditions and 28.5 ± 2 h under hypoxic conditions (P < 0.01). B, The 
number of dAT-MSCs was counted after abnormal cell adhesion and compared to 
the number of nAT-MSCs on days 8, 9, and 10.  
! 48 
 
Fig. 4. dAT-MSCs were impaired in wound healing of ischemic flap mouse 
model. A, A flap model was created and the images of the necrotic areas of mice 
injected with PBS, nAT-MSCs, and dAT-MSCs were captured on day 7 after 
injection. B, The percentage of the necrotic area was calculated based on the 
necrotic area per wound area in mice that were injected with PBS (n = 5), nAT-
MSCs (n = 30), and dAT-MSCs (n = 30). C, The embedded sections were 
examined by hematoxylin and eosin staining for tissue structure, which revealed the 
epidermis, wound, and muscle in each wound site; BS-I Lectin-TRITC was injected 
into the tail vein to observe the vessel formation (red) with fluorescence intensity; 
and the CD45 immunohistochemical staining of inflammatory cells (brown). D, The 
fluorescence intensity was measured using the Image J software program to 
evaluate the number of vessels in each area (n = 20). E, The CD45-positive cells 
were counted and expressed relative to the number nAT-MSCs (n = 10). The data 
represent the average of three independent experiments (mean ± SD); *, P < 0.05; 
**, P < 0.01. Scale bars: 100 µm; Ep, epidermis; W, wound; M, muscle. 
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Fig. 5. dAT-MSCs highly expressed EGR-1 and increased gene expressions 
and phosphorylation of IRS-1 (ser636/639) associated with insulin resistance. 
nAT-MSCs and dAT-MSCs were cultured under normoxic (20% O2) or hypoxic (5% 
O2) conditions. A and B. The mRNA (A) and protein levels (B) of transcription 
factor EGR-1 were examined by a qRT-PCR and an immunoblot analysis, 
respectively normalized to β-actin and Lamin B. C, PTEN and GGPS1 expression 
was determined by a qRT-PCR and normalized to β-actin. D, Insulin (1000nM) was 
added to the culture medium for 60 min to stimulate the phosphorylation of IRS-1 
(P-IRS-1). P-IRS-1 at serine 636/639 and total IRS-1 (T-IRS-1) were analyzed by 
immunoblotting. White and black bars indicate normoxic and hypoxic conditions, 
respectively. The data represent the averages of three independent experiments 
(mean ± SD); *, P < 0.05, **, P < 0.01. N, normoxia; H, hypoxia.  
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Fig. 6. Upregulation of pro-inflammatory cytokine IL-6, growth factors and 
adhesion molecules in dAT-MSCs. A, The mRNA expression level of IL6 was 
assessed by a qRT-PCR and normalized to β-actin and the quantitative protein 
concentration of IL-6 present in cell culture supernatants was measured by 
interleukin-6 (IL-6) high sensitivity human ELISA kit (D6050, R&D systems). B and 
C, The mRNA expression levels were assessed by a qRT-PCR and normalized to 
β-actin to determine the expression of bFGF and TGF-β (B); Cyr61, Col4, and Inαv 
(C). White and black bars indicate normoxic and hypoxic conditions, 
reαααααααααspectively. The data represent the averages of three independent 
experiments (mean ± SD); *, P < 0.05, **, P < 0.01.  
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Fig. 7. HIF-1α directly regulated EGR-1 expression under hypoxic condition. 
A, HIF-1α expression was assessed in nAT-MSCs and dAT-MSCs under normoxic 
and hypoxic conditions by an immunoblot analysis and normalized to Lamin B. B, A 
chromatin immunoprecipitation (ChIP) assay was performed for the EGR-1 
promoter HRE using an anti-HIF-1α antibody under normoxic (20% O2) and hypoxic 
(5% O2, 4 days) conditions. Input samples (1/10 input) were used as an internal 
control; IgG was used as a negative control. The binding of HIF-1α to the EGR-1 
promoter was specified in dAT-MSCs under hypoxic conditions. The data shown 
are the averages of three independent experiments (mean ± SD). *, P < 0.05; **, P 
< 0.01. N, normoxia; H, hypoxia. 
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Fig. 8. PD98059 inhibited phosphorylation of ERK1/2 and EGR-1 expression. 
PD98059 (50 µM) was added to nAT-MSC and dAT-MSC cultures for 60 min that 
were maintained under normoxic (20% O2) or hypoxic (5% O2) conditions. Whole 
cell proteins were prepared for an immunoblot analysis. A, The phosphorylation of 
ERK1/2, and total ERK1/2 (T-ERK1/2), the phosphorylation of AKT at serine 473, 
and total AKT (T-AKT) were examined in treated and untreated cells under 
normoxic and hypoxic conditions. B, The expression levels of EGR-1 and internal 
control β-Actin were also assessed by immunoblotting in treated and untreated cells 
under nomoxic and hypoxic conditions. N, normoxia; H, hypoxia. 
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Fig. 9. The expression levels of genes related to cell proliferation, 
inflammation, and adhesion were down-regulated in dAT-MSCs treated with 
inhibitor. PD98059 (50 µM) was added to nAT-MSC and dAT-MSC cultures for 60 
min that were maintained under normoxic (20% O2) or hypoxic (5% O2) conditions. 
A – C, The mRNA expression levels of the EGR-1 target genes were examined by 
a qRT-PCR and normalized to β-Actin including bFGF and TGF-β (A); IL-6, and 
Cyr61 (B); Col4 and Inαv (C). Controls representative for non-treated cells. The 
data shown are the averages of three independent experiments (mean ± SD). *, P < 
0.05; **, P < 0.01.  
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Fig. 10. The expression of Cyr61 and IL6 at protein levels in dAT-MSCs 
treated with inhibitor. PD98059 (50 µM) was added to nAT-MSC and dAT-MSC 
cultures for 60 min that were maintained under normoxic (20% O2) or hypoxic (5% 
O2) conditions. A, The protein levels of Cyr61 was examined by immunoblot 
analysis, and normalized to β-Actin. B, The quantitative protein concentration of IL-
6 present in cell culture supernatants was measured by ELISA assay. The white 
and black bars indicate normoxic and hypoxic conditions, respectively. Controls 
representative for non-treated cells. The data shown are the averages of three 
independent experiments (mean ± SD). *, P < 0.05; **, P < 0.01.  
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 Fig. 11. Knock-down of EGR-1 decreased protein and genes related to cell 
adhesion and insulin resistance. A, dAT-MSCs were transfected with shRNA 
lentiviral transduction particles targeting EGR-1 (dAT-MSC-shEGR-1). The control 
cells were transfected with lentiviral control (dAT-MSC-Mock). After puromycin 
selection, the cells were cultured under normoxic (20% O2) and hypoxic conditions 
(5% O2) for 4 days. The mRNA and protein levels of EGR-1 were examined by a 
qRT-PCR and an immunoblot analysis, respectively. B, The protein levels of Cyr61 
and the internal control β-Actin were assessed by immunoblot analysis. C, The 
mRNA expression levels of the EGR-1 target genes were assessed by a qPCR and 
normalized to β-Actin including PTEN and GGPS1. The white and black bars 
indicate normoxic and hypoxic conditions, respectively. The data represent the 
averages of three independent experiments (mean ± SD); *, P < 0.05, **, P < 0.01. 
N, normoxia; H, hypoxia. 
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Fig. 12. The expression levels of genes related to cell proliferation, 
inflammation, and adhesion were down-regulated in dAT-MSCs with shEGR-1. 
A, dAT-MSCs were transfected with shRNA lentiviral transduction particles 
targeting EGR-1 (dAT-MSC-shEGR-1). The control cells were transfected with 
lentiviral control (dAT-MSC-Mock). After puromycin selection, the cells were 
cultured under normoxic (20% O2) and hypoxic conditions (5% O2) for 4 days. A 
and B, The mRNA expression levels of the EGR-1 target genes were assessed by 
a qPCR and normalized to β-Actin including bFGF, TGF-β, and IL-6 (A); Cyr61, 
Col4, and Inαv (B). The white and black bars indicate normoxic and hypoxic 
conditions, respectively. The data represent the averages of three independent 
experiments (mean ± SD); *, P < 0.05, **, P < 0.01.  
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Fig. 13. Wound healing capacity was improved in dAT-MSC-shEGR-1 injected 
mice. A, Images of necrotic areas in mice that were injected dAT-MSC-mock and 
dAT-MSC-shEGR-1 were captured at day 7 after transplantation. The percentage of 
the necrotic area was calculated based on the area of necrotic tissue in relation to 
the wound area of mice injected with dAT-MSC-mock (n = 5) and dAT-MSC-
shEGR-1 (n = 6). The knockdown of EGR-1 significantly increased the rate of 
wound healing in comparison to the control group. B, The embedded sections were 
examined by hematoxylin and eosin staining for tissue structure, which revealed the 
epidermis, wound, and muscle in each wound site; BI Lectin-TRITC staining was 
used to reveal the vessel formation (red); CD45 immunohistochemistry staining was 
performed to identify the inflammatory cells (brown). C, The activity of vessel 
formation in each area was measured based on fluorescence intensity using the 
Image J software program (n = 20). D, The number of CD45 positive cells were 
counted relative to the number of dAT-MSC-mock cells (n = 10). The data represent 
the average results from independent experiments (mean ± SD). *, P < 0.05; **, P < 
0.01. Scale bars: 100µm; Ep, epidermis; W, wound; M, muscle. 
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Fig. 14. A schematic illustration of wound healing process with nAT-MSC or 
dAT-MSC transplantation. The wound healing ability of dAT-MSCs was impaired 
due to adhesion molecules and excessive IL-6. This impairment might lead to a 
prolonged inflammation phase and delayed wound healing in comparison to the 
normal wound healing process with nAT-MSC transplantation. 
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Fig. 15. The impairment of dAT-MSCs in gene expression associated with cell 
migration, inflammation, angiogenesis. A and B, The expression of genes) were 
evaluated in nAT-MSCs and dAT-MSCs by qRT-PCR and normalized to β-actin 
including SDF-1, CXCR4, and CXCR7 (A); CCL2 and ANGPTL4 (B). The data 
represent the averages of three independent experiments (mean ± SD); *, P < 0.05, 
**, P < 0.01.  
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Fig. 16. The impairment of dAT-MSCs in wound healing in vitro. A, AT-MSCs 
were treated with mitomycin C for 3 h before the wound was scraped with a p1000 
pipette tip to create a scratch (wound) in vitro (1 mm width). Representative images 
were captured by microscope and analyzed using the WimScratch software 
program (https://mywim.wimasis.com). B, The percentage of uncovered wound 
areas in nAT-MSCs and dAT-MSCs were analyzed at 0 h and 16 h. The presented 
data are the average of ten measurements from five dependent wounds. The data 
represent the averages of three independent experiments (mean ± SD); *, P < 0.05, 
**, P < 0.01. Scale bar: 500 µm 
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Fig. 17. nAT-MSC-derived MVs expressed mesenchymal stem cell surface 
markers and internalize into dAT-MSCs. A, MVs were analyzed and sorted by 
the FACS Vantage SE to determine the expressions of MSC surface markers 
CD105, CD90. B, Internalization ability of MVs into dAT-MSCs was examined under 
microscopy with red fluorescence by PKH26 staining. The images were taken after 
transfecting MVs at 12 h. C, Quantification of MVs transfected-dAT-MSCs 
according to the PKH26 red fluorescence signal was carried out using the FACS 
Vantage SE. 
! 62 
 
Fig. 18. nAT-MSC-derived MVs modulated the expression levels of miRNAs 
and mRNAs in MV-treated dAT-MSCs. A, The expression of miR29c and miR150 
was examined by two-step RT-PCR and normalized to the endogenous control 
(RNU48). B and C, The expression of genes related to cell migration, survival, 
inflammation, and angiogenesis in nAT-MSCs, dAT-MSCs, and dAT-MSCs plus 
MVs, including SDF-1 and its receptors: CXCR4 and CXCR7 (B); CCL2, ANGPTL4, 
and COL1A2 (C). The expression of SDF-1, CXCR4, CXCR7, CCL2, and 
ANGPTL4 was decreased in dAT-MSCs and recovered in dAT-MSCs plus MVs. 
The data represent the average of three independent experiments (mean ± SD); *, 
P < 0.05; **, P < 0.01.  
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Fig. 19. nAT-MSC-derived MVs enhance wound healing ability of dAT-MSCs 
in vitro. nAT-MSC-derived MVs were transfected into dAT-MSCs and compared 
with the control (non-transfected cells) and nAT-MSCs. A, Representative images 
were captured by microscope and analyzed using the WimScratch software 
program (https://mywim.wimasis.com) at 0 h and 16 h. B, The percentage of 
uncovered wound areas from nAT-MSCs, dAT-MSCs, and MV-transfected dAT-
MSCs at 0 h and 16 h. The data are the average of ten measurements from five 
dependent wounds (mean ± SD); *, P < 0.05; **, P < 0.01. Scale bars: 500 µm. 
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Fig. 20. MV-treated dAT-MSCs improved wound healing ability in the flap 
mouse model. A, Images of necrotic areas in mice injected with PBS, nAT-MSCs, 
and dAT-MSCs, or dAT-MSCs plus MVs were captured at day 7. B, The 
percentage of the necrotic area was calculated according to the necrotic area per 
wound area in mice. The data represent the average of three independent 
experiments (mean ± SD); *, P < 0.05; **, P < 0.01.  
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Fig. 21. Tissue structure and early response inflammation were enhanced in 
MV-treated dAT-MSC injected mice. The embedded sections were analyzed at 
day 3 of the flap mouse model. A, Hematoxylin and eosin was stained to examined 
tissue structure, which revealed the epidermis and wound areas in each wound site; 
CD45 immunohistochemical staining of inflammatory cells (brown). B, The numbers 
of CD45-positive cells were counted on three fields per stained section. The data 
present the fold change of CD45-positive cell number among groups. All data 
represent the average of three independent experiments (mean ± SD); *, P < 0.05; 
**, P < 0.01. Scale bars: 200 µm; Ep, epidermis; W, wound. 
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